Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

The DNA methylation inhibitor 5-aza-2'-deoxycytidine (DAC) is approved for the treatment of myelodysplastic syndromes (MDS), but resistance to DAC develops during treatment and mechanisms of resistance remain unknown. Therefore, we investigated mechanisms of primary and secondary resistance to...

Full description

Bibliographic Details
Main Authors: Taichun Qin, Ryan Castoro, Samih El Ahdab, Jaroslav Jelinek, Xiaodan Wang, Jiali Si, Jingmin Shu, Rong He, Nianxiang Zhang, Woonbok Chung, Hagop M Kantarjian, Jean-Pierre J Issa
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3157379?pdf=render

Internet

http://europepmc.org/articles/PMC3157379?pdf=render

Similar Items